3rd December 2025
Latest news
Find all of our recent press releases, stay updated with the latest news and be informed about upcoming events where Curium will be attending.
Please direct any media inquiries to: communications@curiumpharma.com
20th November 2025
CapVest recapitalizes Curium to accelerate its growth strategy, marking the largest transaction in nuclear medicine globally
17th November 2025
Curium Consolidates New Biopharma Business and Sets Up Global Headquarters in Boston, Massachusetts
6th November 2025
Curium Announces First Commercial Doses of diagnostic radiopharmaceuticals in Czech Republic and Slovakia for Patients with Prostate Cancer
15th October 2025
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
8th October 2025
Newcastle & Oxford Set To Benefit From New Technology to Diagnose Disease
21st May 2025
Curium and NRG PALLAS extend collaboration in the supply of essential medical isotope to hospitals
12th May 2025
Curium receives marketing authorization in Switzerland for PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
10th April 2025
Curium enhances its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis
2nd April 2025
Curium Announces Approval of Generic DTPA – Kit for the Preparation of Technetium Tc 99m Pentetate Injection in the U.S.
28th March 2025
Curium completes the acquisition of Monrol as part of its plan to significantly expand Lutetium-177 capacity and PET footprint
30th January 2025
Curium Expands European Supply of Iodine-131 Diagnostic Capsules with New Partnership Agreement with Izotop
28th January 2025
Curium Further Expands European Availability of Pylclari® – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients With Prostate Cancer
12th January 2025
Curium is attending these global congresses in 2025
19th November 2024
Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial
13th November 2024
Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer
1st October 2024
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
24th September 2024
Curium announces the official opening of its new Netherlands facility for the production of Lutetium-177 – a game changer therapy isotope for cancer patients worldwide
10th September 2024
Curium Announces Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – is now available in Spain
9th July 2024